It can also affect appetite, fullness, blood sugar, and metabolic health
Microdosing tirzepatide means beginning at doses well below the FDA-approved starting point, sometimes as low as 0.25 mg, and titrating upward gradually over weeks or months
Notably, the effect of tirzepatide as an anti-obesity medication is being investigated in the ongoing SURMOUNT clinical trial programme, in a similar manner to the assessment of semaglutide 2.4 mg for obesity in the Semaglutide Treatment Effect in People with obesity (STEP) programme [27]
These practices, established while appetite suppression is strong, become your foundation once the medication exits your system
GLP-1s are prescribed to adults with a BMI over 30, or adults with a BMI over 27 who also have obesity-related conditions, such as prediabetes, diabetes, high blood pressure, high cholesterol, sleep apnea, and fatty liver disease
Daily injectables (liraglutide) require daily attention